UBE3A reinstatement as a disease-modifying therapy for Angelman syndrome
Half a century ago, Harry Angelman reported three patients with overlapping clinical features, now well known as Angelman syndrome. Angelman syndrome is caused by mutations affecting the maternally inherited UBE3A gene, which encodes an E3-ubiquitin ligase that is critical for typical postnatal brain development. Emerging evidence indicates that UBE3A plays a particularly important role in the nucleus. However, the critical substrates that are controlled by UBE3A remain elusive, which hinders the search for effective treatments. Moreover, given the multitude of signalling mechanisms that are derailed, it is unlikely that targeting a single pathway is going to be very effective. Therefore, expectations are very high for approaches that aim to restore UBE3A protein levels. A particular promising strategy is an antisense oligonucleotide approach, which activates the silenced paternal UBE3A gene. When successful, such treatments potentially offer a disease-modifying therapy for Angelman syndrome and several other neurodevelopmental disorders.
|Developmental Medicine and Child Neurology|
|Organisation||Department of Neuroscience|
Elgersma, Y, & Sonzogni, M. (Monica). (2021). UBE3A reinstatement as a disease-modifying therapy for Angelman syndrome. Developmental Medicine and Child Neurology. doi:10.1111/dmcn.14831